| Assessment Status | Rapid Review Complete |
| HTA ID | 20024 |
| Drug | Indacterol/mometasone furoate |
| Brand | Atectura® |
| Indication | As maintenance treatment of asthma in adults and adolescents 12 years and older not adequately controlled with inhaled corticosteroids and inhaled short acting β2 agonists. |
| Assessment Process | |
| Rapid review commissioned | 13/05/2020 |
| Rapid review completed | 10/06/2020 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that Indacterol/mometasone furoate (Atectura®) be considered for reimbursement*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.